For comparative context, researchers may reference Semaglutide, a selective GLP-1 receptor agonist, and Tirzepatide, a dual GIP/GLP-1 receptor agonist, when examining how incremental receptor targeting across this compound class affects metabolic pathway outcomes
These GLP-1 medications are revolutionizing obesity care but how soon can you expect to see results
The potential of GHK as an anti-aging peptide * Corresponding author: Warren Ladiges Mailing address: Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA
So small that most cats won't even feel it going in
A peptide calculator removes the guesswork entirely
This centrally produced GLP-1 reaches specific receptors located in key structures involved in appetite regulation, such as the paraventricular nucleus, the lateral septum, the nucleus accumbens and the lateral parabrachial nucleus.2,3,6 Furthermore, it promotes aversive responses, inhibits neuroinflammation and gastric emptying, and stimulates sympathetic tone and thermogenesis in experimental models.2,4,6 Activation of GLP-1R on neurons in the arcuate nucleus stimulates the production of pro-opiomelanocortin (POMC), which in turn inhibits neurons that produce neuropeptide Y (NPY), thereby generating an appetite-suppressing response.2 GLP-1 production has also been reported in the olfactory bulb, although its significance remains unclear.2,6 GLP-1R has been identified in the sinoatrial node, atrial and ventricular myocytes, and vascular endothelium